中证报指出，这种方法无需依赖TCR分子的三维结构信息。只需对筛选出的多个"关键按钮"进行同步改 造，即可增强TCR分子"抓住"癌细胞的能力，从而将T细胞打造成效率超群的"超级守护者"。经改造的T 细胞活化水平更高、杀伤力更强，且能精准辨别敌我、避免误伤健康细胞。目前，该研究在动物模型中 疗效显著，为开发新一代高效、精准的癌症免疫疗法提供了崭新的思路。 据中证报报道，中国科学院分子细胞科学卓越创新中心（生物化学与细胞生物学研究所）研究团队与合 作者开发出"组氨酸扫描法"，能快速定位T细胞表面的T细胞受体（TCR）分子中负责识别癌细胞并启 动清除程序的"关键位点"。对这些位点进行"改造升级"后，TCR分子便化身为高灵敏度的增强版"安检 仪"，显著提升了T细胞清除癌细胞的能力。该策略已在实验中展现出良好的抗癌效果。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 公司方面，据中证报表示，A股相关概念股有翰宇药业、新开源等。 ...

证券日报网讯 2月25日，新开源在互动平台回答投资者提问时表示，截至2月10日收市，公司股东户数 约为19100户。 （文章来源：证券日报） ...

Core Insights - The report by Frost & Sullivan indicates a significant increase in the daily usage of enterprise-level large models in China, with a rise to 37 trillion tokens in the second half of 2025, marking a 263% increase from 10.2 trillion tokens in the first half [1][3]. Group 1: Market Dynamics - The primary drivers for enterprises using large models shifted from enhancing product performance and customer experience in the first half of 2025 to improving operational efficiency and R&D effectiveness in the second half [3]. - The market for enterprise-level large models is rapidly consolidating around leading vendors, with the top three models (Qwen, Doubao, and DeepSeek) accounting for over 70% of daily token consumption in the second half of 2025, compared to less than half in the first half [3][4]. Group 2: Vendor Performance - Alibaba Cloud's Qwen model saw its market share nearly double to 32.1% in the second half of 2025, with a growth rate of 14.4% [3][4]. - The report highlights that enterprises are increasingly favoring fewer vendors to reduce long-term operational costs related to interface maintenance and version management, creating higher migration barriers for leading vendors [4]. Group 3: Open Source Trends - There is a notable increase in enterprises' willingness to adopt open-source models, with the proportion of closed-source users planning to add open-source options doubling from 22.6% in the first half to 48.5% in the second half of 2025 [4]. - Chinese companies accounted for 90.2% of the global new open-source large models introduced in the second half of 2025, significantly outpacing international competitors [4]. Group 4: Competitive Landscape - The competition among domestic open-source models has expanded beyond single-point performance to include size, deployment flexibility, and cost control [5]. - Since its launch in 2023, Qwen has released over 400 models, achieving over 1 billion downloads and extending its language capabilities to 201 languages, establishing itself as the leading open-source model globally [5].

| Models 2,647,509 Filter by name | Full-text search * Inference Available 1J Sort: Trending | | --- | --- | | Qwen/Qwen3.5-397B-A17B | Z zai-org/GLM-5 | | [% Image-Text-to-Text · .: 403B · Updated about 16 hou ... · ¿ 303k · + · ♡ 952 | To Text Generation · .: 754B · Updated 11 days ago · · 2 179k · 4 · ♡ 1.48k | | 2 nvidia/personaplex-7b-v1 | 글 Nanbeige/Nanbeige4.1-3B | | 11 Audio-to-Audio · Updated 8 days ago · 2 539k · ♡ 2.18k | To Text Generation · .: 4B · Updated 2 days ago · ¿ 178k · · ♡ 756 | | @ Mi ...

证券日报网讯 2月24日，新开源在互动平台回答投资者提问时表示，截至2月13日收市，公司股东户数 为18735户。 （文章来源：证券日报） ...

股价异动原因 全额现金收购占用流动资金：本次收购需支付2.193亿元现金，而公司2025年三季报货币资金为9912.46 万元，需通过"自有资金+银行融资"组合支付。市场担忧短期现金流压力，尤其标的公司新开源2025年 前三季度净利润为1678万元，同比出现下滑。控股股东减持计划叠加负面情绪：同期公告显示控股股东 徐杨顺拟减持不超过2.82%股份，进一步加剧市场对资金需求的疑虑。 经济观察网拓山重工（001226）(001226.SZ)在披露收购新开源（300109）51%股权的公告后股价出现下 跌，主要受交易方案细节、市场对短期资金压力的担忧以及技术面调整等因素影响。根据截至2026年2 月13日的数据，公司股价在公告后次日(2月13日)单日下跌8.69%，收盘报48.86元。 股价短期涨幅较大后回调：在收购公告前，公司股价近20日涨幅为0.83%，2月11日一度触及54.76元高 位，接近布林带上轨(54.46元)技术面数据。公告后获利盘兑现导致抛压加剧。主力资金净流出：2月13 日成交额放大至1.90亿元，换手率达5.09%，且当日振幅达7.98%，显示资金分歧明显技术面数据。 MACD指标差离值由正转 ...

经济观察网 新开源（300109）近期在资产重组、高管变动、财务业绩及股东结构方面出现一系列动 态。公司重大资产重组方案可能出现重大调整，涉及收购标的博爱新开源生物科技有限公司的股权结构 变更，原投资方因资金问题未能实缴注册资本，已引入新股东接手部分义务。深交所曾就此次重组的高 溢价问题发出问询函，要求补充披露标的资产估值及核心竞争力等细节。 高管变动 截至2026年1月31日，新开源股东户数为18,295户，较1月20日减少1,205户，环比下降6.18%。同期股价 小幅上涨，融资余额增加。 以上内容基于公开资料整理，不构成投资建议。 2025年前三季度公司主营收入9.51亿元，同比下降14.36%；归母净利润2.01亿元，同比下降35.39%。单 季度第三季度收入及利润均出现下滑，毛利率为43.58%。 股东人数情况 高级副总经理于江涛因工作调动不再担任该职务，但继续担任公司非独立董事。此次变动可能影响公司 管理结构，于江涛2024年薪酬为59.60万元，在董事及高管中排名居中。 业绩经营情况 ...

- The report does not contain any quantitative models or factors for analysis[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42]

Group 1 - New Source (stock code: 300109.SZ) held an investor meeting on February 6, 2023, in Shanghai, attended by 37 institutions including Shenwan Hongyuan and Everbright Securities [2][15] - Since 2026, 18 A-share listed companies from Henan have received institutional research, with Xiangyu Medical leading with 208 institutions participating [16][23] - The demand for core products, particularly PVP series products and their applications in emerging fields, was a major focus during the meeting [3][17] Group 2 - New Source is a leading high-tech enterprise in the research, development, and production of PVP series products, with a total domestic production capacity of 57,000 tons per year, accounting for 53% of global capacity and a 34% global market share [18] - PVP is widely used in various sectors, including daily chemicals, pharmaceuticals, food and beverage, materials, and new energy, with significant applications in solid-state batteries and photovoltaic cells [18][4] - The company expects to sell approximately 4,000 tons of PVP in the new energy sector by 2025, with a projected 20% increase in 2026 [4][19] Group 3 - The price of PVP products has been affected by rising raw material costs due to the European energy crisis and the Russia-Ukraine conflict, leading to increased prices and profit margins, which are not expected to be sustainable [5][19] - Another core product, Euriz (PVM/MA), has a high single-ton price with a gross margin of approximately 60%-70%, with expected shipments of about 900 tons in 2025 [20] - New Source has made strategic investments in five cell and gene therapy companies to enhance its competitive edge in the precision medical field [20][21] Group 4 - New Source's invested companies are progressing well, with one product entering NDA approval and several others in clinical stages, indicating potential for future growth and IPO opportunities [21] - The company's governance structure is relatively decentralized, with major shareholders expressing confidence in the long-term development of the company and intentions to increase their holdings [21][22] - Institutional interest in Henan-listed companies reflects recognition of their investment value, with many companies being leaders in their respective sectors [25]

证券日报网2月9日讯 ，新开源（300109）在接受调研者提问时表示，公司高度重视股东沟通与投资者 关系管理，前期已就公司经营发展、治理安排等事项与前十大股东进行充分沟通，各方已形成高度一致 意见。公司将全力以赴抓好生产经营，持续提升经营质量与核心竞争力，切实为全体股东创造长期价 值。目前公司股权结构相对分散，公司控股股东、实际控制人及其一致行动人始终看好公司长期发展前 景，具备增持意向。未来在合规前提下、择机通过处置部分个人体外资产筹措资金，用于增持公司股 份，进一步优化股权结构、稳定控制权，彰显对公司未来发展的坚定信心。 ...